Merck : Darmstadt, Germany to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis

• Company to present 54 abstracts across its MS portfolio - MAVENCLAD^® (cladribine tablets), Rebif^® (interferon beta-1a) and investigational evobrutinib
• New long-term data and real-world evidence further characterise efficacy and safety of MAVENCLAD^®
• New MAVENCLAD^® and Rebif^® safety data to be shared demonstrating no increased risk of respiratory viral infections

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced it will present data on its approved and investigational multiple sclerosis (MS) treatments at MSVirtual2020: 8^th Joint ACTRIMS-ECTRIMS Meeting. The Company will present 54 abstracts at the meeting, taking place virtually from 11-13 September 2020, including new efficacy and real-world safety data on MAVENCLAD^® (cladribine) tablets and new safety data for Rebif^® (interferon beta-1a).

In addition, data will be presented on the efficacy profile of evobrutinib, an investigational, oral, highly selective Bruton's Tyrosine Kinase inhibitor (BTKi), through 108 weeks of treatment in the Phase II open-label extension (OLE) in adult patients with relapsing multiple sclerosis (RMS). Preclinical data will also be presented providing insights into evobrutinib's potential impact on progression in MS.

'The broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives,' said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck KGaA, Darmstadt, Germany. 'Much of our data provide insights on how MAVENCLAD^® and Rebif^® affect the risk of respiratory viral infections and COVID-19 outcomes in MS patients. These insights will help support clinicians as they make treatment decisions for their patients living with MS.'

Key MAVENCLAD^® (cladribine) tablets data include:

• Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined unique active (CUA) lesion count in the first six months of MAVENCLAD^® treatment for highly active RMS
• New data evaluating cumulative relapse incidence over five years in patients enrolled in the MAVENCLAD^® CLARITY and CLARITY Extension trials
• Late-breaking interim data from the CLASSIC-MS study on the long-term efficacy and real-world treatment patterns for patients receiving MAVENCLAD^®, with eight to 14 years of follow up, will be available as part of the late-breaker sessions from 25 September 2020
• Results from a post hoc analysis from the CLARITY Extension and the impact of MAVENCLAD^® on the prevalence of disability improvement over five years, as measured by the Expanded Disability Status Scale (EDSS)
• Results from the MAGNIFY and CLARIFY studies regarding clinical outcomes in patients with COVID-19 infection during these Phase IV studies of MAVENCLAD^® for the treatment of MS will be available as part of the late-breaker sessions from 25 September 2020
• Updated post-approval safety data of MAVENCLAD^® in the treatment of MS, including respiratory viral infections and findings that the safety profile was consistent with that from the clinical development program

Key Rebif^® (interferon beta-1a) data include:

• Post-approval results on the safety of Rebif^® in the treatment of MS, showing no new safety signals

Key evobrutinib data include:

• Efficacy results of the Phase II OLE in patients treated with evobrutinib 75 mg BID (twice a day), as measured by annualized relapse rate from Week 48 to Week 108
• Safety results from the ≥60 week Phase II OLE
• Preclinical data demonstrating evobrutinib's potential to reduce CNS compartmentalized inflammation thought to drive the progression of disability seen in MS

Additional Merck KGaA, Darmstadt, Germany activities at MSVirtual2020:

• Live presentation 'Exploring the role of real-world data in multiple sclerosis' chaired by Prof. Gavin Giovannoni, Chair of Neurology, Barts and The London School of Medicine and Dentistry (12 September 2020, 14:30-15:30 EDT; recording available after the event)
• Two product theatres on demand throughout the congress starting from 11 September 2020, 11:45 EDT
  • 'Multiple sclerosis patient management: update from the UK' by Dr. Wallace Brownlee, MS Specialist Neurologist, National Hospital for Neurology and Neurosurgery, and MS researcher at Queen Square MS Centre, University College London Institute of Neurology
  • 'Real-world multiple sclerosis management: what can we learn from MSBase?' by Dr. Suzanne Hodgkinson, Associate Professor, University of New South Wales, and a senior consultant neurologist at Liverpool Hospital, New South Wales, Australia

Following the conclusion of MSVirtual2020, Merck KGaA, Darmstadt, Germany will be hosting 'Mastering the Neuroscience of Unconscious Bias,' the inaugural virtual event for the company`s I'M IN initiative, a diversity, equity and inclusion effort started in February 2019. I'M IN is a US-based initiative started by the Neurology & Immunology franchise, which aims to explore solutions together with healthcare providers to improve equity within the healthcare ecosystem.

Below is the full list of Merck KGaA, Darmstadt, Germany abstracts accepted for presentation at ACTRIMS-ECTRIMS 2020:

MAVENCLAD® (cladribine tablets) Presentations
Title	Authors	Presentation ID	Presentation Details
Reduced Grey Matter Atrophy in Patients With Relapsing Multiple Sclerosis Treated With Cladribine Tablets	Battaglini M, Sormani M P, Luchetti L, Gentile G, Cortese R, Alexandri N, De Stefano N	P0231	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Marco Battaglini
Reduction in CUA MRI Lesions in the First 6 Months of Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Study	De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L. Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S	P0382	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Nicola De Stefano
Durable Efficacy of Cladribine Tablets: Cumulative Relapse Incidence Over 5 years in CLARITY and CLARITY Extension	Giovannoni G, Rammohan K, Leist T, Coyle P K, Keller B, Jack D, Alexandri N	P0202	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Gavin Giovannoni
Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients Receiving Cladribine Tablets, Evaluated by Expanded Disability Status Scale	Sormani M P, Signori A Giovannoni G, Alexandri N	P0201	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Maria Pia Sormani
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections	Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D	P0415	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Gavin Giovannoni
Clinical Outcomes in Patients With COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis	Karan R, Roy S, Alexandri N	LB1151	Session: Latebreaker ePoster Date: 25-26 September 2020 Time: Available from 9am EDT on 25 September 2020 Presenter: Radmila Karan
Treatment Satisfaction in Patients With Highly-active Relapsing Multiple Sclerosis Treated With Cladribine Tablets: CLARIFY-MS Study Interim Analysis	Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B	P1066	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Bruno Brochet
Initial Findings From a Dynamic Cohort Study of Patients With Multiple Sclerosis: A Proactive Approach for Safety and Comparative Effectiveness	Sabidó, M, Batech M, Foch C, Boutmy E, Verpillat P	P0470	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Meritxell Sabidó
Characteristics of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Five European Countries: Multi-year Chart Review	Zeng F, Harty G, Wong SL, Maslova E, Schade R, Row B	P0846	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Feng Zeng
Characterization of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Germany Since Marketing Authorization	Zeng F, Harty G, Wong SL, Uebler S, Maslova E, Schade R, Row B, Ellenberger D, Stahmann A	P0847	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Feng Zeng
CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients Receiving Cladribine Tablets - Interim Data with 8-14 Years Follow-up	Giovannoni G, Leist T, Aydemir A, Verdun Di Cantogno E, on behalf of the CLASSIC-MS Steering Committee	LB1229	Session: Latebreaker ePoster Date: 25-26 September 2020 Time: Available from 9am EDT on 25 September 2020 Presenter: Thomas Leist
Age-related Efficacy of Cladribine Tablets in Patients With Relapsing-remitting MS in the CLARITY Extension Study	Freedman M, Pardo G, De Stefano N, Aldridge J, Hyvert Y, Galazka A, Lemieux C	P0284	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Mark Freedman
Cladribine Tablets in Patients with RRMS and Active SPMS After Suboptimal Response to Prior DMD (MASTER-2 and CLICK-MS): Initial Baseline Demographics	Miravelle A, Katz J, Robertson D, Hayward B, Walsh JS, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ	P0310	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Augusto Miravelle
Treatment-emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in two Phase 3 Trials in Multiple Sclerosis	Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson L, Leist TP	P0411	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Jiwon Oh
Identification and Characterization of Adherence Trajectory Subgroups in Patients With MS Initiating Once- or Twice-daily Oral Disease-modifying Drugs	Cisternas MG, Rajagopalan D, Leszko M, Andrade K, Phillips AL	P0967	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Amy Phillips
Real-world Patient-level Costs of Administering Infusion Disease-modifying Drugs: A US Retrospective Claims Database Analysis	Kozma CM, Roberts NL, Phillips AL	P1052	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Chris Kozma
Value-added Benefits of a Nurse/Pharmacy-led Service for Patients With Multiple Sclerosis Treated Over 2 Years With Cladribine Tablets in the UK	Morgan K, Vernon K, Ayer M	P1069	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Kate Morgan
Demonstrating the Value of a Patient Support Program for Multiple Sclerosis Patients Prescribed Cladribine Tablets in Ireland at the end of Year 1	Morgan K, Joseph B, Williams V, Kelly M	P1015	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Kate Morgan
Low Discontinuation Rate and Side-effect Burden After Switching to Cladribine Tablets: Canadian Experience from the adveva® Patient Support Program	Oh J, Giacomini P, Devonshire V, Clift F, Lemieux C, Sabido M, Allignol A, Freedman M	P0880	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Jiwon Oh
Cladribine Tablets Versus Other Disease-modifying Therapies in Achieving Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients - Network Meta-analysis	Piasecka-Stryczyńska K, Rolka M, Kaczyński Ł, Górecka M, Wójcik R, Adamek I, Kaczor MP, Rejdak K	P0040	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: K. Piasecka-Stryczynska
MS Disease-modifying Therapy Sequencing - Natalizumab to Cladribine Tablets - Experience in 46 Patients	Ziemssen T, Penner IK, Wagner T, Huebschen M, Mueller B, Buescher T, Richter J, Posevitz-Fejfar A	566	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Tjalf Ziemssen
Switching disease modifying treatment in relapsing multiple sclerosis: Delphi consensus of the Demyelinating Group of the Spanish Society of Neurology	Saiz A, Aguera E, Moral E, Brieva L, Rodriguez-Antiguedad A, Casanova-Estruch B, Jordi R, Meca-Lallana V, Garcia-Merino JA, Costa-Frossard L, Arnal-Garice C, Landete L, Meca-Lallana J, Blanco Y, Matías-Guiu J, Ares A, Martínez-Ginés ML, Ara JR, Llaneza M, Castillo-Trivino T, Romero L, Perez-Sempere A, González-Platas M, Mendibe-Bilbao M	P0401	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Luis Brieva
CLADQoL (CLADribine Tablets - evaluation of Quality of Life) Study: Evaluating QoL 12 Months After Treatment Initiation with Cladribine Tablets	Penner IK, Pul R, Kallmann BA, Raji A, Richter J, Wagner T, Mueller B, Buescher T, Posevitz-Fejfar A	P0849	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Iris-Katharina Penner
Effects of Cladribine on Proliferation, Survival and Cytokine Release of Human Astrocytes	Eixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Comabella M, Montalban X, Espejo C	P0330	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Herena Eixarch
Real-world Experience With Cladribine in the MSBase Registry	Butzkueven H, Spelman T, Verdun di Cantogno E, Fabris J, Zeng F, G Harty	P0907	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Helmut Butzkueven
2-Chlorodeoxyadenosine (Cladribine) Preferentially Inhibits the Biological Activity of Microglia Cells	Aybar F, Marcora S, Eugenia Samman M, Perez MJ, Pasquini JM, Correale J	P0270	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Jorge Correale
Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS)	Lieberman D, Mangat H, Allen-Philby K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J, Ford H, Giovannoni G, Hobart J, Hooper R, Hussain T, Walker N, Macmanus D, Mihaylova B, Pavitt S	P0196	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: David Lieberman
Predicting Long-term Sustained Disability Progression in Multiple Sclerosis: Application in the CLARITY Trial	Sharmin S, Bovis F, Sormani MP, Butzkueven H, Kalincik T and the MSBase study group	P0131	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: S Sharmin
A Clinical Data Summary for Cladribine Patients Treated at least 12 Months - A Swedish Nationwide Study of the Long-Term Effectiveness and Safety of Cladribine (IMSE 10)	Forsberg L, Kågström S, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom AM, Burman J, Martin C, Sundström P, Gunnarsson M, Piehl F, Olsson T	P0276	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: L Forsberg
Impact of Cladribine Tablets on Brain Volume Protection in Highly Active MS	Raji A, Winkler G	P0586	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: A Raji
Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience	Bain J, Jones A, Overholt S, Guenette M, Selchen D, Jiwon Oh	P0319	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: J Bain
Switching From Ocrelizumab to Cladribine: Real-world Data	O'Neill DTD, Sharma M, Gonzales B, Vandenheuvel M, Tse B, Hodgkinson SJ	P0399	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: D O'Neill
The Effect of Cladribine Upon Naïve and Activated CD4+ T Regulatory Cells in MS Patients	Verma ND, Al-Atiyah R, O'Neill D, Sharma M, Tran CT, Hall BM, Hodgkinson SJ	P0406	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Suzanne Hodgkinson
Rebif® (interferon beta-1a) Presentations
A Systematic Review and Meta-analyses of Pregnancy and Fetal Outcomes in Women with Multiple Sclerosis. IMI2 ConcePTION	Lopez-Leon S, Geissbuehler Y, Sabidó M, Turkson, M, Wahlich C, Morris J	P0278	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Meritxell Sabidó
Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections	Freedman M S, Guehring H, Murgasova Z, Jack D	P0370	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Mark Freedman
Effect of Neutralizing Antibodies on Pharmacodynamic Biomarkers of Subcutaneous Interferon β-1a in REFLEX and REFLEXION	Freedman MS, Holmberg KH, Fluck M, Hyvert H, Stinchi S, D'Urso V, Dangond F	P0323	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Mark Freedman
Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 MS Within 2 yrs of a First Clinical Demyelinating Event in REFLEX	Kuhle J, Leppert D, Comi G, De Stefano N, Kappos L, Freedman MS, Issard D, Roy S	P0032	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Sanjeev Roy
Effect of age on Effectiveness and Discontinuation of Subcutaneous Interferon beta-1a, and Healthcare Utilization, in Patients With Multiple Sclerosis	Sabidó M, Allignol A Marhardt K, Vermersch P, Boutmy EF	P0320	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Patrick Vermersch
Comparing Infection-related Outcomes in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data	Bove R, Kozma C, Phillips AL, Harlow DE, Lobo C	P0451	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Riley Bove
Assessment of the Effectiveness of a Cognitive Behavioral Program for Fatigue (FACETS +) in 110 French Patients with Relapsing Remitting Multiple Sclerosis (RR MS): A randomized, controlled trial (RCT)	Hemelin F, Marie Claire G, Olivier H, Marie B, Frederic B	P1095	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Fanny Hamelin
Impact of Interferon-beta Exposure During Early Pregnancy on Relapse Rate	Tokic M, Thiel S, Litvin N, Ciplea A, Gold R, Hellwig K	P1126	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: M Tokic
Evobrutinib Presentations
Clinical Relapse Rates in Relapsing MS Patients Treated with the BTK Inhibitor Evobrutinib: Results of an Open-Label Extension to Phase II Study	Montalban X, Arnold D L, Weber MS, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Dangond F, Wolinsky JS	P0197	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Fernando Dengond
Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis During an Open-label Extension to a Phase II Study	Montalban, X Arnold D L, Weber M S, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Zima Y, Dengond F, Tomic D, Wolinsky JS	P0235	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Fernando Dengond
Effect Of Evobrutinib, a BTK Inhibitor, on Immune Cell and Immunoglobulin Levels in Relapsing MS: An Open-Label Extension to a Phase II Study	Montalban X, Shaw J, Dangond F, Martin EC, Grenningloh R, Ying Li, Weber MS	P0070	Session: ePoster Time: Available from 9am EDT on 11 September 2020 Presenter: Jamie Shaw
Evobrutinib, a Highly Selective BTK Inhibitor, Prevents Antigen-activation of B Cells and Ameliorates B Cell-mediated Experimental Autoimmune Encephalomyelitis	Torke S, Pretzsch R, Häusler D, Grenningloh R, Boschert U, Brück W, Weber MS	P0334	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Sebastian Torke
Expression of Bruton's Tyrosine Kinase in B Cell-rich Meningeal Infiltrates in two Models of Progressive MS	Kebir H, Ceja G, Miller MC, Li C, May MJ, Vite CH, Church ME, Grenningloh R, Boschert U, Alvarez JI	P0962	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Kebir Hania
T-bet+ B-cell Development in MS: Association with Bruton's Tyrosine Kinase Activity and Targeting by Evobrutinib	Rijvers L, Melief MJ, van Langelaar J, Wierenga-Wolf AF, Marieke van Ham S, Boschert U, Grenningloh R, Smolders J, van Luijn MM	P0403	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT 11 September 2020 Presenter: Liza Rijvers
The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Ameliorates Meningeal Inflammation in Experimental Autoimmune Encephalomyelitis	Kim S, Boschert U Grenningloh R, Bhargava P	P0404	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Pavan Bhargava
The Validity and Applicability of the PROMIS SF v2.1 - Physical Function (MS) 15a: A new PROMIS® Short Form for Assessing Physical Function in Relapsing and Progressive Multiple Sclerosis Types	Kamudoni P, Amtmann D, Johns J, Cook K, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Henke C	P1062	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Paul Kamudoni
The Interpretation and Clinical Application of the PROMIS® SF v1.0 - Fatigue (MS) 8b: A PROMIS Short Form for Assessing Fatigue in Relapsing and Progressive Multiple Sclerosis	Kamudoni P, Johns J, Cook K, Salem R, Henke C, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G,Wundes A, Amtmann D	P1061	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Paul Kamudoni
General MS Franchise
Identifying Gaps in Knowledge, Skills and Confidence Among MS Specialists to Facilitate Improved MS Care	Schmierer K, Peniuta M, Oh J, Leist T, Lazure P, Péloquin S	P1100	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Klaus Schmierer
An Investigation Into the Role and Impact That Carers Play in Consultations Between Healthcare Professionals and People With MS	Langdon D, Sumelahti M L, Potra S, Alroughani R, on behalf of the MS in the 21st Century initiative, Verdun Di Cantogno E	P1006	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Dawn Langdon
Characterization of Age-related Changes in Circulating T cells in Multiple Sclerosis and Normal Controls: A Pilot Study	Zuroff LR, Li R, Shinoda K, Rezk A, Bar-Or A	P0952	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: LR Zuroff
Treatment and Care Management, Clinical Outcomes and Mobility Impairment in People With or Without MS Aged ≥50 Years: Observational 6-year Analysis	Freeman L, Lucas A, Zhou J, Hayward B, Livingston T	P0176	Session: ePoster Date: 11-13 September 2020 Time: Available from 9am EDT on 11 September 2020 Presenter: Terrie Livingston